Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerry Avorn

Showing results (101-110 of 436) with videos related to

Pageof 44
Sort By:
JAMA Internal Medicine|March 9, 2016
Inaccurate Reporting of Insulin Reimbursement-ReplyJing Luo, Jerry Avorn, Aaron S Kesselheim
Kidney International|April 5, 2003
The nephrologist's role in the management of calcium-phosphorus metabolism in patients with chronic kidney diseaseWolfgang C Winkelmayer, Raisa Levin, Jerry Avorn
JAMA|May 26, 2018
An Incomplete Prescription: President Trump's Plan to Address High Drug PricesAmeet Sarpatwari, Jerry Avorn, Aaron S Kesselheim
JAMA Internal Medicine|August 25, 2015
Trends in Medicaid Reimbursements for Insulin From 1991 Through 2014Jing Luo, Jerry Avorn, Aaron S Kesselheim
The New England Journal of Medicine|July 27, 2017
The Price of Crossing the Border for MedicationsMichael Fralick, Jerry Avorn, Aaron S Kesselheim
The New England Journal of Medicine|April 18, 2014
Using a drug-safety tool to prevent competitionAmeet Sarpatwari, Jerry Avorn, Aaron S Kesselheim
JAMA|December 14, 2016
Factors Influencing Prescription Drug Costs in the United States-ReplyAmeet Sarpatwari, Jerry Avorn, Aaron S Kesselheim
Plos One|February 18, 2014
Clinicians' contributions to the development of coronary artery stents: a qualitative study of transformative device innovationAaron S Kesselheim, Shuai Xu, Jerry Avorn
The New England Journal of Medicine|May 7, 2015
Progress and Hurdles for Follow-on BiologicsAmeet Sarpatwari, Jerry Avorn, Aaron S Kesselheim
JAMA|August 24, 2016
The High Cost of Prescription Drugs in the United States: Origins and Prospects for ReformAaron S Kesselheim, Jerry Avorn, Ameet Sarpatwari
Pageof 44

Showing results (101-110 of 436) with videos related to

Sort By:
Pageof 44
JAMA Internal Medicine|March 9, 2016
Inaccurate Reporting of Insulin Reimbursement-ReplyJing Luo, Jerry Avorn, Aaron S Kesselheim
Kidney International|April 5, 2003
The nephrologist's role in the management of calcium-phosphorus metabolism in patients with chronic kidney diseaseWolfgang C Winkelmayer, Raisa Levin, Jerry Avorn
JAMA|May 26, 2018
An Incomplete Prescription: President Trump's Plan to Address High Drug PricesAmeet Sarpatwari, Jerry Avorn, Aaron S Kesselheim
JAMA Internal Medicine|August 25, 2015
Trends in Medicaid Reimbursements for Insulin From 1991 Through 2014Jing Luo, Jerry Avorn, Aaron S Kesselheim
The New England Journal of Medicine|July 27, 2017
The Price of Crossing the Border for MedicationsMichael Fralick, Jerry Avorn, Aaron S Kesselheim
The New England Journal of Medicine|April 18, 2014
Using a drug-safety tool to prevent competitionAmeet Sarpatwari, Jerry Avorn, Aaron S Kesselheim
JAMA|December 14, 2016
Factors Influencing Prescription Drug Costs in the United States-ReplyAmeet Sarpatwari, Jerry Avorn, Aaron S Kesselheim
Plos One|February 18, 2014
Clinicians' contributions to the development of coronary artery stents: a qualitative study of transformative device innovationAaron S Kesselheim, Shuai Xu, Jerry Avorn
The New England Journal of Medicine|May 7, 2015
Progress and Hurdles for Follow-on BiologicsAmeet Sarpatwari, Jerry Avorn, Aaron S Kesselheim
JAMA|August 24, 2016
The High Cost of Prescription Drugs in the United States: Origins and Prospects for ReformAaron S Kesselheim, Jerry Avorn, Ameet Sarpatwari
Pageof 44